Clinical trials: Bleeding Disorder
Immune Thrombocytopenia (ITP)
A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP
The purpose of this study was to compare the ability of eltrombopag in combination with a short course of high-dose dexamethasone to induce sustained response off treatment in patients with newly-diagnosed ITP versus 1-3 cycles…
- Trial name
- XPAG-ITP (NCT04346654)
- Testing
- Eltrombopag, Dexamethasone
- Where
- 10 sites in Germany
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Osteoarthritis
Blood Loss Reduction After Total Knee Arthroplasty. Comparison Topical Tranexamic Acid vs Platelet Rich Plasma
The investigators will include patients who will be schedule for total knee arthroplasty with a diagnosis of osteoarthritis. The patients will be divided in two groups.
- Trial name
- NCT02650856
- Testing
- Group 1 Tranexamic Acid, Group 2 Platelet rich plasma
- Where
- Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de Nuevo Leon
Intracerebral Hemorrhage
High-Dose Deferoxamine in Intracerebral Hemorrhage
The main purpose of this study is to determine whether treatment with deferoxamine mesylate is of sufficient promise to improve outcome before pursuing a larger clinical trial to examine its effectiveness as a treatment for brain…
- Trial name
- HI-DEF (NCT01662895)
- Testing
- Deferoxamine, Normal saline
- Where
- 29 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Beth Israel Deaconess Medical Center
Blood Coagulation Disorders, Hemorrhage
Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures
The purpose of this study is to evaluate prophylactic fresh frozen plasma transfusion in patients with moderately elevated international normalized ratios (INR) prior to undergoing an invasive procedure.
- Trial name
- NCT02637427
- Testing
- Fresh frozen plasma transfusion
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Rutgers, The State University of New Jersey
Coronary Artery Disease, Atherosclerosis
SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy
The purpose of this study is to see if one month of dual antiplatelet therapy (DAPT) combined with the placement of the Synergy® Stent with IVUS (intravascular ultrasound) is safe for patients who are at high risk of bleeding…
- Conditions
- Coronary Artery Disease, Atherosclerosis, Stent Placement
- Trial name
- SYNIVUS-DAPT (NCT03606642)
- Testing
- Dual Antiplatelet (DAPT) Therapy, The Synergy® stent
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- HonorHealth Research Institute
Hemophilia A
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
This is an open-label, non-randomized, efficacy, safety and pharmacokinetic (PK) study comparing octocog alfa and rVIII-SingleChain.
- Trial name
- NCT01486927
- Testing
- rVIII-SingleChain, Octocog alfa
- Where
- 56 sites in United States, Australia and 18 more
- Volunteers
- 175 people
- Sponsor
- CSL Behring
Aortic Valve Stenosis, Aneurysm of Ascending Aorta
Progel Vascular Sealant
This study is being conducted to evaluate the safety and effectiveness of the Progel Vascular Sealant for use in vascular reconstructions to achieve adjunctive hemostasis by mechanically sealing areas of leakage.
- Conditions
- Aortic Valve Stenosis, Aneurysm of Ascending Aorta, Aortic Valve Disorder, Bicuspid Valve Disorder
- Trial name
- NCT01959503
- Testing
- Progel Vascular Sealant, Gelfoam Plus
- Where
- 19 sites in United States
- Volunteers
- 158 people
- Sponsor
- C. R. Bard
Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm
Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage
The purpose of this study is to test whether treatment with a drug called Simvastatin prevents and improves outcome in patients who have Subarachnoid bleeding.
- Trial name
- NCT00487461
- Testing
- Simvastatin 40 mg, Simvastatin 80 mg
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Illinois at Chicago
Purpura, Thrombocytopenic, Idiopathic and Hepatitis C
Eltrombopag Phase III Study In Chinese Chronic ITP Patients
This randomized, double-blind and open-label phase III study aimed to determine the efficacy, tolerance and safety of eltrombopag in Chinese chronic primary immune thrombocytopenia (ITP) adult subjects.
- Trial name
- NCT01762761
- Testing
- eltrombopag
- Where
- 18 sites in China
- Volunteers
- 155 people
- Sponsor
- Novartis Pharmaceuticals
Thrombocythemia, Essential
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2
This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.
- Trial name
- NCT04081220
- Testing
- IMG-7289
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Subarachnoid Hemorrhage
Ventriculostomies in SAH: ICP Open or Not?
The purpose of this study is explore how cerebrospinal fluid (CSF) drainage impacts outcomes for patients diagnosed with subarachnoid hemorrhage (SAH).
- Trial name
- VISION (NCT00787020)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Duke University
Intracerebral Hemorrhage, Stroke
The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial
The purpose of this academic lead study is to determine if a treatment strategy of early intensive blood pressure (BP) lowering compared to conservative BP lowering policy in patients with elevated blood pressure within 6 hours…
- Conditions
- Intracerebral Hemorrhage, Stroke, Hypertension
- Trial name
- INTERACT2 (NCT00716079)
- Testing
- Blood pressure management policies
- Where
- 62 sites in United States, Argentina and 17 more
- Volunteers
- 2,839 people
- Sponsor
- The George Institute
Von Willebrand Disease
Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery
The purpose of the study is to assess the efficacy and safety of recombinant von Willebrand factor (rVWF) with or without ADVATE in major and minor elective surgical procedures in adult patients with hereditary severe von…
- Trial name
- NCT02283268
- Testing
- Recombinant von Willebrand Factor (rVWF)
- Where
- 34 sites in United States, Australia and 11 more
- Volunteers
- 24 people
- Sponsor
- Baxalta now part of Shire
Blood Coagulation Disorders, Acute Major Bleeding
Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy
The purpose of this study is to evaluate efficacy, safety and tolerance of BERIPLEX® P/N (Kcentra) compared with plasma in regard to rapid reversal of coagulopathy induced by coumarin derivatives in subjects who require immediate…
- Trial name
- NCT00708435
- Testing
- Beriplex® P/N (Kcentra), Fresh frozen plasma
- Where
- 69 sites in United States, Belarus and 4 more
- Volunteers
- 216 people
- Sponsor
- CSL Behring
Immune Thrombocytopenia
Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)
Study in patients with persistent and chronic Immune Thrombocytopenia (ITP), who have failed to respond or relapsed after prior therapy, with a platelet count <30,000/µL.
- Trial name
- NCT04056195
- Testing
- SKI-O-703
- Where
- 27 sites in United States, Greece and 3 more
- Volunteers
- 61 people
- Sponsor
- Oscotec Inc.
Intracerebral Haemorrhage, Intraventricular
Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone
This is an exploratory single-center prospective study of 20 subjects with primary basal ganglia ICH who will receive early MIPS in combination with perioperative pioglitazone treatment.
- Trial name
- ENRICHPLUS (NCT05582707)
- Testing
- Pioglitazone 15mg
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Maryland, Baltimore
Immune Thrombocytopenic Purpura
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
The primary objective of this study was to assess the long term safety of fostamatinib in subjects with persistent/chronic ITP
- Trial name
- NCT02077192
- Testing
- Fostamatinib Disodium
- Where
- 55 sites in United States, Australia and 13 more
- Volunteers
- 123 people
- Sponsor
- Rigel Pharmaceuticals
Intracranial Aneurysm, Subarachnoid Hemorrhage
PRET: Patients Prone to Recurrence After Endovascular Treatment
The PRET study aims at comparing two types of coils used in the endovascular treatment of intracranial aneurysms. The first type made of platinum has been used for more than 15 years.
- Trial name
- PRET (NCT00626912)
- Testing
- endovascular coil embolization
- Where
- 32 sites in United States, Canada and 4 more
- Volunteers
- 447 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Epistaxis, Blood Pressure
The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.
Nosebleeds (epistaxis) are a frequent cause of emergency department visits, reportedly inciting 1 in 200 visits. They are most common in those less than ten and older than seventy, often occurring in the winter months secondary…
- Trial name
- NCT02285634
- Testing
- Oxymetazoline 0.05%, Phenylephrine 0.25%, Lidocaine 1% plus epinephrine 1:100,000
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Mayo Clinic
Factor VIII Deficiency
A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A
Primary Objective: To evaluate the efficacy of BIVV001 as a prophylaxis treatment in prophylaxis treatment arm. Secondary Objectives: To evaluate the efficacy of BIVV001 as a prophylaxis treatment.
- Trial name
- XTEND-1 (NCT04161495)
- Testing
- efanesoctocog alfa (BIVV001)
- Where
- 47 sites in United States, Argentina and 17 more
- Volunteers
- 159 people
- Sponsor
- Bioverativ, a Sanofi company